Shelley Force Aldred is the senior author on a recent paper describing the development of a new anti-cancer drug called TNB-383B

Shelley Force Aldred, scientist and fearless biotech entrepreneur, is the senior author on a recent paper describing the development of a new anti-cancer drug called TNB-383B, and the team at Teneobio just signed a large partnership deal with AbbVie to take the new drug into the clinic. TNB-383B is a next-generation T-cell engaging bispecific antibody that may offer new hope for multiple myeloma patients that have failed to respond to standard treatments. It's inspiring how great science has an impact on people and the world around us and we are so proud of Shelley, a Hipower Ring 6 member. hashtag#HipowerUp -- Paper: https://lnkd.in/gpbkA9U Press release: https://lnkd.in/geH8Szf